Keep up to Date and Stay Informed

Sign up for email alerts to receive company updates including press releases, filings and special announcements straight to your inbox.

Sign me up for:

Latest 10-K

View Latest 10-K

Stock Information

Symbol

Nasdaq: KTRA

Price

Change

Volume

52 week Low/High

Day Low/High

Company Overview

Kintara Therapeutics is a biopharmaceutical company focused on the development and commercialization of new cancer therapies.

VAL-083, is a "first-in-class" small molecule DNA-targeting agent that is currently being evaluated in a biomarker-driven Phase 2 clinical trial for the treatment of Unmethylated MGMT recurrent glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. We are also exploring VAL-083 in a Phase 2 trial as a therapy for front-line Unmethylated MGMT GBM and we may study other solid tumors, including ovarian cancer and pediatric CNS tumors.

REM-001 Therapy consists of three parts, a laser light source, a light delivery device and the drug REM-001 (collectively, REM-001 Therapy). REM-001 is a second generation photosensitizer drug that has undergone late stage clinical development, and which we believe possesses multiple advantages over earlier generation PDT compounds. Our lead indication for REM-001 Therapy is unresectable cutaneous metastatic breast cancer (CMBC), a disease that may affect individuals with advanced breast cancer and for which effective treatment options are limited. For this and similar cutaneous applications, the light delivery device is a simple and easy to use fiber optic wand that the physician employs to directly illuminate the tumor with light

Company

Kintara Therapeutics, Inc.
12707 High Bluff Drive
Suite 200
San Diego, CA, United States 92130

Investor Relations

T: (604) 629-5989
ir@kintara.com

Transfer Agent

Mountain Share Transfer, LLC
2030 Powers Ferry Road SE
Suite #212
Atlanta, Ga. 30339
United States
T: 404-474-3110
F: 404-816-8830
mountainsharetransfer.com